VACDIAGN BIOTECHNOLOGY CO LTD has a total of 13 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2011. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are GENIMMUNE N V, AVM BIOTECHNOLOGY LLC and INST BIOTECHNOLOGII I ANTYBIOT.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | EPO (European Patent Office) | 1 | |
#4 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Xu Jianqing | 13 |
#2 | Huang Yang | 13 |
#3 | Zhang Xiaoyan | 9 |
#4 | Gao Mingquan | 5 |
#5 | Sun Jiahao | 3 |
#6 | Wang Lu | 3 |
Publication | Filing date | Title |
---|---|---|
CN110923266A | Recombinant virus vector, immune composition containing same and application | |
CN112079924A | PD-L1 targeted binding agents and uses thereof | |
WO2020248156A1 | Pd-l1-targeting binding agent and use thereof | |
CN109575141A | A kind of CD4 helper T lymphocyte epitope fusogenic peptide and its vaccine | |
WO2019061297A1 | Cd4 helper t-cell epitope fusion peptide and vaccine thereof | |
CN103221064A | Immune methods against influenza viruses and combinatorial vaccines thereof |